References of "Stevenaert, Achille"
     in
Bookmark and Share    
Peer Reviewed
See detailPresurgical Octreotide Treatment in Acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Acta Endocrinologica (1993), 129(1), 18-20

The effects of octreotide pretreatment before surgery were assessed in 48 acromegalic patients who underwent trans-sphenoidal surgery to remove pituitary adenoma, and compared with 107 patients who did ... [more ▼]

The effects of octreotide pretreatment before surgery were assessed in 48 acromegalic patients who underwent trans-sphenoidal surgery to remove pituitary adenoma, and compared with 107 patients who did not receive octreotide before surgery. Pretreated patients received octreotide 100 micrograms, thrice daily for 3 to 6 weeks (group 1), or 100 to 500 micrograms, thrice daily for 3 to 39 months (group 2). Total remission of symptoms was seen in 54%. Partial remission of symptoms occurred in 39%. Octreotide pretreatment reduced plasma GH levels by > or = 50% in all patients. GH levels were reduced to < 2 micrograms/1 in 3/14 group 1 cases and 13/34 group 2 cases. Tumour shrinkage occurred in 56.5% of patients. Marked tumour shrinkage (> 25%) occurred in more group 2 patients (10/32 vs 1/14). The tumour was soft in 39 patients, firm in 6 and hard in 3 cases. Soft consistency aided surgical removal of adenomas. Remission was greater in enclosed adenomas than in invasive tumours in both octreotide pretreated and nonpretreated acromegalics (76 vs 30%). Remission was more likely if the adenoma was less than 16 mm. Remission rate was significantly greater (p < 0.05) in all octreotide pretreated than in untreated patients for enclosed adenoma, but not for invasive adenoma. Octretide pretreatment can be recommended for three to four months prior to surgery. [less ▲]

Detailed reference viewed: 23 (0 ULg)
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Journal of Endocrinological Investigation (1993), 16(1-8), 137

Detailed reference viewed: 1 (0 ULg)
Peer Reviewed
See detailLe traitement des adénomes à prolactine : utilisation d'un nouvel agoniste dopaminergique à longue durée d'action, la cabergoline, chez 56 patients
Beckers, Albert ULg; Abs, R.; Demez, Pierre ULg et al

in Médecine et Hygiène (1993), 51(1990), 1978-1980

Nous avons utilisé la cabergoline, un nouvel agoniste dopaminergique, dans le traitement des adénomes hypophysaires à prolactine. Cinquante-six patients atteints de micro-adénome dans 35 cas et de ... [more ▼]

Nous avons utilisé la cabergoline, un nouvel agoniste dopaminergique, dans le traitement des adénomes hypophysaires à prolactine. Cinquante-six patients atteints de micro-adénome dans 35 cas et de macroadénome dans 21 cas ont été traités durant des périodes variant entre 1 et 17 mois à des doses de cabergoline variant entre 0,25 mg et 2 mg par semaine, prises à raison de 1 à 4 fois par semaine. Cette nouvelle substance nous est apparue extrêmement efficace et très bien tolérée [less ▲]

Detailed reference viewed: 30 (0 ULg)
Peer Reviewed
See detailAspects cliniques de la neoplasie endocrinienne multiple de type 1 (NEM-1).
Ghuysen, Alexandre ULg; Stevenaert, Achille ULg; Beckers, Albert ULg

in Revue Médicale de Liège (1993), 48(6), 309-63

Detailed reference viewed: 19 (1 ULg)
See detailDecreased number and defect of the initialization process of corticotropin-releasing hormone receptors in adenomatous corticotrophs
Smets, G.; Abs, R.; Verhelst, J. et al

in The 75th Annual meeting of the Endocrine society - Abstract book (1993)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailThe treatment of prolactinomas with cabergoline : results in 56 patients
Demez, Pierre ULg; Verhaert, G.; Stevenaert, Achille ULg et al

in Journal of Endocrinological Investigation (1993), 16

Detailed reference viewed: 6 (0 ULg)
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 3rd International pituitary congress - Abstract book (1993)

Detailed reference viewed: 3 (0 ULg)
See detailThe treatment of prolactinomas with cabergoline : results in 56 patients
verhaert, g; demez, p; abs, r et al

in Acta Clinica Belgica (1993), (48),

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailDecreased number and defect of the internalization process of corticotropin-releasing hormone receptors in adenomatous corticotrophs
verhelst, j; Abs, R.; Beckers, Albert ULg et al

in Acta Clinica Belgica (1993), 48

Detailed reference viewed: 2 (0 ULg)
See detailThe treatment of prolactinomas with cabegoline : results in 56 patients
Verhelst, J.; Abs, R.; Verhaert, G. et al

in Neuro-endocrinologie PRL, VI International prolactin congress - Abstract book (1993)

Detailed reference viewed: 15 (0 ULg)
Peer Reviewed
See detailAspects cliniques de la néoplasie endocrinienne multiple de type 1 (NEM-1)
Ghuysen, Alexandre ULg; Beckers, Albert ULg; Stevenaert, Achille ULg

in Médecine & Chirurgie Digestives (1993), 22(8), 468-470

Detailed reference viewed: 19 (3 ULg)
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly.
Stevenaert, Achille ULg; Harris, A. G.; Kovacs, K. et al

in Metabolism : Clinical and Experimental (1992), 41(9 Suppl. 2), 51-8

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered ... [more ▼]

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered for 3 to 6 weeks before surgery in 12 patients and for 4 to 39 months in 25 patients. The clinical response was judged as excellent or good in 10 of 12 patients from group I and in 23 of 25 patients from group II. Marked reduction (ie, greater than 50% of initial values) in serum growth hormone (GH) levels was seen in all patients, with levels to less than 5 micrograms/L in 68% of patients and less than 2 micrograms/L in 27%. Insulin-like growth factor 1 (IGF-1) levels decreased to within normal limits in half the cases. During long-term treatment, an escape phenomenon could be seen. Varying degrees of tumor shrinkage were seen in more than 50% of cases. During surgery, with regard to the relative ease or difficulty in removing the tumor, the consistency of the tumor and the separation of normal from pathological tissue, no significant difference was observed between patients given octreotide and those from control series. Morphological changes in adenomatous tissue were rather small. The surgical outcome was similar in the pretreated series as in the control series, except in enclosed adenomas, which showed a tendency to a higher success rate. Since octreotide improves both the clinical condition and hormonal parameters and induces varying degrees of tumor shrinkage, it is potentially useful as an adjunct to surgery. Morphological data suggest that octreotide exercises a functional inhibitory effect on GH release. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailAldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus.
Beckers, Albert ULg; Abs, R.; van der Auwera, B. et al

in Journal of Clinical Endocrinology and Metabolism (1992), 75(2), 564-70

A 63-year-old female presented with the extremely rare occurrence of an aldosterone-secreting adrenocortical adenoma as part of the syndrome of multiple endocrine neoplasia type 1 (MEN1). Only two other ... [more ▼]

A 63-year-old female presented with the extremely rare occurrence of an aldosterone-secreting adrenocortical adenoma as part of the syndrome of multiple endocrine neoplasia type 1 (MEN1). Only two other MEN1 patients were reported in the literature with hyperaldosteronism. The patient's MEN1 syndrome consisted of the association of primary hyperparathyroidism due to parathyroid adenoma, a prolactinoma, and a toxic multinodular goiter. Elevated basal and meal-stimulated serum PP levels without demonstrable pancreatic tumor were also found. Genetic analysis of the aldosterone-secreting adenoma with DNA markers localized on chromosome 11 showed loss of heterozygosity in tumor DNA. Since the MEN1 syndrome is caused by loss of the tumor suppressor gene on chromosome 11 in the 11q13 region, it is probable that the same mechanism is associated with the formation of the adrenocortical adenoma. [less ▲]

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailExperimental Acute Traumatic Injury of the Adult Rat Spinal Cord by a Subdural Inflatable Balloon: Methodology, Behavioral Analysis, and Histopathology
Martin, Didier ULg; Schoenen, Jean ULg; Delree, P. et al

in Journal of Neuroscience Research (1992), 32(4), 539-50

We describe an experimental model to produce closed traumatic injuries to the spinal cord of adult rats. This model uses an inflatable balloon that is introduced in the dorsal subdural space and moved to ... [more ▼]

We describe an experimental model to produce closed traumatic injuries to the spinal cord of adult rats. This model uses an inflatable balloon that is introduced in the dorsal subdural space and moved to a location rostral to the laminectomy site. The spinal cord trauma can be graded by varying either the duration of compression or the volume of saline used to inflate the balloon. The locomotor deficit of animals with various degrees of injury has been assessed at increasing delays after trauma. The parameters generating transient or definitive deficits of varying intensity were defined. Some injured animals underwent nuclear magnetic resonance imaging. Detailed histopathological studies demonstrated that the extent of the spinal lesion was significantly correlated with the physical parameters of compression and with the severity of the behavioral deficit. [less ▲]

Detailed reference viewed: 19 (3 ULg)